MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
1.630
-0.110
-6.32%
After Hours: 1.752 +0.122 +7.49% 19:26 11/12 EST
OPEN
1.750
PREV CLOSE
1.740
HIGH
1.750
LOW
1.600
VOLUME
608.76K
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.4350
MARKET CAP
295.15M
P/E (TTM)
-1.8162
1D
5D
1M
3M
1Y
5Y
1D
Century Therapeutics Reports Third Quarter 2026 Financial Results
NASDAQ · 5h ago
Century Therapeutics reports Q3 EPS (11c), consensus (11c)
TipRanks · 20h ago
Century Therapeutics GAAP EPS of -$0.11 beats by $0.01
Seeking Alpha · 20h ago
Century Therapeutics, Inc. Q3 Loss Declines
NASDAQ · 20h ago
*Century Therapeutics 3Q Rev $0.00 >IPSC
Dow Jones · 20h ago
*Century Therapeutics 3Q Loss $23.5M >IPSC
Dow Jones · 20h ago
Press Release: Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Dow Jones · 20h ago
Weekly Report: what happened at IPSC last week (1102-1106)?
Weekly Report · 3d ago
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.